A retrospective study evaluating the efficacy of CPX-351 as Induction Chemotherapy in Younger Patients (<60 years) and comparing to Older Patients (> 60 years) with Acute Myeloid Leukemia.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Oct 2022 Results assessing clinical and molecular data from adult patients with newly diagnosed AML-MRC or t-AML treated with CPX-351, published in the Clinical Lymphoma, Myeloma & Leukemia.
10 Dec 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
10 Dec 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com